Skip to main content
Clinical Trials/EUCTR2005-001670-27-GB
EUCTR2005-001670-27-GB
Active, not recruiting
Not Applicable

Reversibility of cerebrovascular endothelial dysfunction in diabetes: the role of allopurinol.

Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship0 sites24 target enrollmentOctober 17, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type Two Diabetes Mellitus
Sponsor
Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship
Enrollment
24
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 17, 2005
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship

Eligibility Criteria

Inclusion Criteria

  • Type II diabetes of less than 5 years' duration treated with diet, metformin, thiazolidinediones or a combination of above
  • Age \> 40 years
  • Normal full Bruce protocol exercise tolerance test
  • Favourable temporal bony window
  • Stable glycaemic control (HbA1c \< 9\.0%)
  • Stable cholesterol (total cholesterol \< 7\.5
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • \>70% extra\-cranial internal carotid artery stenosis
  • Known coronary arterial disease
  • Significant co\-morbidity
  • Contra\-indication to or indication for administration of allopurinol
  • Concurrent azathioprine or 6\-mercaptopurine therapy
  • Insulin or sulphonylurea therapy
  • Serum creatinine concentration greater than 250 micromoles per litre

Outcomes

Primary Outcomes

Not specified

Similar Trials